GLP-1 receptor agonist
A class of medication (including semaglutide and tirzepatide) that affects insulin, appetite, and weight. Increasingly used in PMOS, on a clinician’s lead.
GLP-1 receptor agonists are a class of medication that mimic a gut hormone involved in blood sugar control and appetite. Brand and generic names include semaglutide and tirzepatide (the latter acts on a second receptor as well).
They work through several mechanisms: improving insulin response, slowing stomach emptying, and reducing appetite signals. In people with PMOS, they have shown effects on insulin sensitivity, weight, and cardiometabolic markers.
The PMOS-specific evidence base is growing but is not as deep as it is for inositol or metformin. Use in PMOS is increasingly common, but it remains a clinician-led decision, with access, cost, side effects, and pregnancy planning all part of the conversation. These are prescription medications, not first-line lifestyle steps, and they are best understood as following from the foundational interventions rather than replacing them.